Observational study on time on treatment with abiraterone and enzalutamide

Giuseppe Fallara1,2,3*, Ingela Franck Lissbrant4, Johan Styrke5, Francesco Montorsi1,2, Hans Garmo3,6, Pär Stattin3*

1 Division of Experimental Oncology/Unit of Urology URI, IRCCS Ospedale San Raffaele, Milan, Italy, 2 Vita-Salute San Raffaele University, Milan, Italy, 3 Department of Surgical Sciences, Uppsala University, Uppsala, Sweden, 4 Department of Oncology Institute of Clinical Sciences, The Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden, 5 Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden, 6 Regional Cancer Centre, Uppsala/Orebro, Uppsala University Hospital, Uppsala, Sweden

* fallara.giuseppe@hsr.it (GF); par.stattin@surgsci.uu.se (PS)

Abstract

Introduction

The aim of this study was to assess time on treatment with abiraterone and enzalutamide, two androgen receptor targeted (ART) drugs, the impact on time on treatment of time interval without drug supply between prescription fillings, and adherence to treatment.

Material and methods

By use of data from The National Prostate Cancer Register, The Prescribed Drug Registry and the Patient Registry, time on treatment with the abiraterone and enzalutamide was analyzed in all men with castration resistant prostate cancer (CRPC) in Sweden 2015–2019. Three time intervals between consecutive fillings, i.e. time without drug supply, were assessed. Adherence to the treatment was evaluated by use of the Medication Possession Ratio. Kaplan Meier analysis and multivariable Cox regression model were used to assess factors affecting time on treatment.

Results

Between January 2015 and October 2019, 1803 men filled a prescription for abiraterone and 4 534 men filled a prescription for enzalutamide. With a time interval of 30 days or less between two fillings, median time on treatment was 4.9 months (IQR 2.6–11.7) for abiraterone and 8.0 months (IQR 3.6–16.4) for enzalutamide. In sensitivity analyses, allowing for no more than 14 days without drug supply between fillings, median time on treatment was 3.9 months (IQR 2.1–9.0) for abiraterone and 5.9 months (IQR 2.8–12.1) for enzalutamide. Allowing for any time period without drug between fillings, median time on treatment was 5.7 months (IQR 2.7–14.0) for abiraterone and 9.8 months (IQR 4.4–21.0) for enzalutamide. Adherence to treatment was above 90% for both drugs.
Conclusion

Time on treatment with abiraterone and enzalutamide was shorter in clinical practice than in randomized controlled trials and varied almost two-fold with time interval without drug. Adherence to treatment was high. The main limitation of our study was the lack of data on use of chemotherapy.

Introduction

Several randomized clinical trials (RCT) have shown that abiraterone and enzalutamide, two androgen receptor targeted (ART) drugs, increase survival and improve quality of life in men with metastatic castration resistant prostate cancer (mCRPC) [1–5]. Therefore, several national guidelines including those in Sweden, as well as guidelines from the European Association of Urology (EAU) and American Urological Association (AUA) recommend their use, either before or after chemotherapy [6–8]. In these RCTs, the median time on treatment was around 14 months for abiraterone and 17 months for enzalutamide in chemo-naïve men and around 8 months in post-docetaxel setting for both drugs. There has been concern that use of ART drugs in clinical practice is continued too long and given that these drugs are expensive and are used by a large number of men with mCRPC, this could have large financial implications. A wide range in time on treatment for these drugs has been reported in previous observational studies, ranging from 3 to 20 months (S1 Table) [9–25].

The aim of this study was to assess time on treatment for abiraterone and enzalutamide, the effect on time on treatment by the allowed time interval without drug between fillings and adherence to the treatment in a nationwide population-based study of men with mCRPC in Sweden.

Materials and methods

The National Prostate Cancer Register (NPCR) of Sweden

Since 1998, the NPCR includes data on 98% of all newly diagnosed cases of prostate cancer (PCa) registered in the Swedish Cancer Registry, to which reporting is mandatory by law [26,27]. Comprehensive data on cancer characteristics, work-up, and primary treatment are registered but no data on the subsequent disease trajectory are registered.

Prostate Cancer data Base Sweden (PCBaSe)

In PCBaSe, NPCR has been linked to other national health care registers and demographic databases by use of the Swedish personal identification number. In this study we used data from PCBaSe RAPID 2018 that includes all men diagnosed with PCa until December 31, 2018 and with follow-up until October 31, 2019 [28].

The Prescribed Drug Registry

The Prescribed Drug Registry comprises all filled prescribed drugs to the entire Swedish population since July 2005 [29]. It contains the following information: the Swedish person identity number, the dispensed drug name and ATC-code (Anatomical Therapeutic Chemical classification), the defined daily dose (DDD), the amount of drug dispensed and the date of dispensing. In this registry there are no data on drugs delivered in hospital or delivered over the
counter without a prescription. We used The Prescribed Drug Registry to search for filled prescriptions for abiraterone and enzalutamide (ATC codes L02BX03 and L02BB04, respectively).

The National Patient Registry
The National Patient Registry includes information regarding in-patient care in Sweden from 1987 and an increasing capture of out-patient care since 2000. This registry was used to compute the Charlson comorbidity index (CCI) based on discharge diagnoses up to 10 years prior to ART initiation, and to retrieve data for chemotherapy before ART initiation [30].

The Cause of Death Registry
Since 1991, the Cause of Death Registry collects information on the date and cause of death for all persons registered in Sweden. The validity of data in this registry has been found to be high for PCa death [31].

Subsidized use of abiraterone and enzalutamide
The Dental and Pharmaceutical Benefits Agency is a Swedish government agency whose remit is to decide which pharmaceutical products should be subsidized. Both abiraterone and enzalutamide are subsidized. The New Therapies council together with national guideline groups make recommendations and formulates follow-up protocols for new drug therapies after market authorization.

Study design and patient selection. This study included men in NPCR who were diagnosed with PCa until December 31, 2018 and who had filled a first prescription for abiraterone or enzalutamide in the Prescribed Drug Registry between July 1, 2015 and October 31, 2019. Data were accessed in May 2020 for analysis.

The only indication for abiraterone and enzalutamide was mCPRC until June 15, 2018 when abiraterone was licensed for men with metastatic hormone sensitive PCa [32]. Thus, we assumed that men who had filled a prescription for abiraterone or enzalutamide were in mCRPC state, with the exception of men who had filled a prescription for abiraterone less than six months after PCa diagnosis, who were excluded. The use of the first prescribed ART was assessed, i.e. time on treatment for abiraterone after initial use of enzalutamide and vice versa was not analyzed (S1 Fig).

We used data from PCBaSe on PCa risk category [26] and primary treatment, defined as curative (radical prostatectomy or radiotherapy) or non-curative (androgen deprivation therapy [ADT], active surveillance or deferred treatment), age at ART initiation, duration of ADT (defined as the time from the date of initiation of GnRH agonist/antagonist, bicalutamide or orchiectomy whichever came first, to the start date of ART), time from diagnosis to ART start, CCI, and previous chemotherapy.

Study outcomes. The primary outcome of the study was time on treatment for abiraterone and enzalutamide. Time on treatment started at the date of the first filling of the drug. To define end of time on treatment we used the defined daily dose (DDD) registered in the Prescribed Drug Registry. For both abiraterone and enzalutamide the registered DDD is the number of days for which the drug is supplied in the filling, which is usually 28 days. After DDD days from the filling, there is sometimes a time period before the date of the next filling, i.e. the patient does not fill the next prescription exactly DDD days after the previous filling which means that the patient is without drug supply (Fig 1). We allowed this time period to be 30 days. If this period was longer than 30 days, then the date of the end of supply of the previous filling was considered as end of treatment. If the date of end of supply was at a later calendar date than date of death, then the latter date was used as end of treatment.
By allowing for a time period beyond the last drug supply immortal time bias is introduced
[33]. As a sensitivity analysis we allowed 14 days or shorter and we also analysed time on treat-
ment without restriction on the time without supply. We also assessed adherence to treatment
and predictors of treatment stop.

**Statistical analysis.** Cumulative incidence curves were created for time on treatment cen-
soring at end of follow-up without an observed drug stop, considering death and other causes
for treatment stop as competing risks. Median time on treatment was estimated by use of
Kaplan Meier method, i.e. sum of cumulative incidence of death and drug stop.

Adherence was assessed by use of the Medical Possession Ratio (MPR), defined as the ratio
between the sum of the total days of supply and the total number of days in the observation
period [34]. Mean time on treatment was calculated as the area under the survival curve fitted
by a Weibull distribution [35–37]. The product of adherence and mean time on treatment was
used to estimate the duration of time on treatment covered by drug supply.

We combined the use of abiraterone and enzalutamide in order to assess factors that were
associated with drug stop by use of Kaplan Meier plots and in univariable and multivariable
Cox regression models.

The study was approved by the Research Ethics Board in Uppsala (PCBaSe RAPID 2018
Dnr 2017–263) that waived the informed consent requirement.

**Results**

6 337 men had filled a prescription of ART, of whom 1 803 had filled a prescription for abira-
terone and 4 534 for enzalutamide (S1 Fig).

At date of diagnosis, 751 men (42%) on abiraterone and 1 877 men (42%) on enzalutamide
had metastatic disease. Accordingly, the majority of men had undergone non-curative primary
treatment (Table 1).

Median age at drug initiation was 77 years (interquartile range [IQR] 71–82) for abirater-
one and 76 years (IQR 71–81) for enzalutamide. Median time from diagnosis to start of treat-
ment was 5.5 years for both abiraterone and enzalutamide. Time from ADT start to
Table 1. Baseline characteristic of 6337 men in prostate cancer data base Sweden (PCBaSe) RAPID 2018 who had filled a prescription for abiraterone or enzalutamide in addition to GnRH.

| PCa risk category, n (%) | Abiraterone (n = 1803) | Enzalutamide (n = 4534) |
|-------------------------|------------------------|-------------------------|
| At date of diagnosis    |                        |                         |
| Low/Intermediate-risk   | 373 (21)               | 834 (18)                |
| High-risk/Locally advanced | 669 (37)             | 1805 (40)               |
| Metastatic              | 751 (42)               | 1877 (42)               |
| Missing                 | 10 (0)                 | 18 (0)                  |
| Primary treatment, n (%)|                        |                         |
| Non-curative            | 1260 (70)              | 3076 (68)               |
| Curative treatment      | 482 (27)               | 1307 (29)               |
| Missing                 | 61 (3)                 | 151 (3)                 |
| PSA at diagnosis, ng/mL |                        |                         |
| Median (IQR)            | 31.4 (12–124)          | 33.0 (12–127)           |
| Missing                 | 12 (0.7)               | 36 (0.8)                |

| At date of initiation of ART |
|-------------------------------|
| Age, Years                    | 76.7 (71.1–82.1)       | 76.1 (71–81.4)          |
| Median (IQR)                  |                        |                         |
| Calendar year of prescription, n (%) |                     |                         |
| 2015                          | 235 (13)               | 725 (16)                |
| 2016                          | 245 (14)               | 1053 (23)               |
| 2017                          | 390 (22)               | 930 (21)                |
| 2018                          | 437 (24)               | 1049 (23)               |
| 2019*                         | 496 (27)               | 777 (17)                |
| Time from diagnosis to ART start, n (%) |                     |                         |
| Median (IQR), years          | 5.6 (2.6–10.3)        | 5.5 (2.6–9.7)           |
| 0.5–1 year                   | 84 (5)                 | 212 (5)                 |
| 1–3 years                    | 446 (25)               | 1126 (25)               |
| 3–5 years                    | 296 (16)               | 750 (16)                |
| 5–10 years                   | 493 (27)               | 1379 (30)               |
| >10 years                    | 484 (27)               | 1067 (24)               |
| Time from start of ADT to start of ART, n (%) |                     |                         |
| ≤ 0.5 year                   | 34 (2)                 | 77 (2)                  |
| 0.5–1 year                   | 89 (5)                 | 253 (6)                 |
| 1–3 years                    | 535 (30)               | 1345 (29)               |
| 3–5 years                    | 354 (20)               | 906 (20)                |
| 5–10 years                   | 550 (30)               | 1114 (24)               |
| >10 years                    | 241 (13)               | 839 (18)                |
| Charlson comorbidity index, n (%) |                     |                         |
| 0                             | 644 (36)               | 1622 (36)               |
| 1–2                           | 614 (34)               | 1488 (33)               |
| 3–4                           | 366 (20)               | 907 (20)                |
| ≥ 5                           | 179 (10)               | 517 (11)                |
| Previous chemotherapy, n (%)  |                        |                         |
| Not recorded in PAR           | 1601 (89)              | 3999 (88)               |

(Continued)
abiraterone or enzalutamide start was more than 5 years in almost 40% of men and less than 1 year in less than 10% of men. The majority of men, almost 70%, had CCI $\leq 2$.

**Median time on drug according to different time intervals without drug supply**

Median time on treatment was 4.9 months (IQR 2.6–11.7) for abiraterone and 8.0 months (IQR 3.6–16.4) for enzalutamide, using 30 days or less as time interval between two consecutive fillings without drug supply (Fig 2). We also assessed shorter and longer time intervals between two fillings. For a shorter time interval, up 14 days without drug supply, median time on treatment was shorter, 3.9 months (IQR 2.1–9.0) for abiraterone and 5.9 months (IQR 2.8–12.1) for enzalutamide. For a longer time interval without drug supply, allowing for any time period without drug before the next filling, median time on treatment became longer, 5.7 months (IQR 2.7–14.0) for abiraterone and 9.8 months (IQR 4.4–21.0) for enzalutamide.

**Adherence**

Adherence assessed as Medication Possession Ratio was 97% for abiraterone and 95% for enzalutamide. Less than 5% of men on abiraterone and 8% on enzalutamide had low adherence (< 80%). By use of a time interval of 30 days, the duration of mean time on treatment covered by drug was 8.5 months for abiraterone and 11.6 months for enzalutamide (S2 Fig).

**Factors affecting time on treatment**

A shorter time on treatment was found in old men, in men who had receive non-curative primary treatment, in men with high comorbidity, and in men with short time on ADT prior to ART (Fig 3). These findings remained after adjustments in the multivariable Cox regression analysis (Table 2).

Men who received ART after chemotherapy had a shorter time on treatment than men who received ART before chemotherapy, however only 12% of men were reported to have received chemotherapy (S3 Fig).

**Discussion**

In this population-based, nationwide registry study, time on treatment in clinical practice was 5 months for abiraterone and 8 months for enzalutamide for 30 days or less without supply between two fillings. Adherence to treatment was above 90% for both abiraterone and enzalutamide.
The main strength of this study is the virtually complete capture of all men in a country on abiraterone or enzalutamide in 2015–2019. In addition, we had access to data that allowed us to assess time on treatment according to different time intervals, i.e. time without drug supply between fillings. However, this study is not devoid of limitations. We did not have data on PSA levels that confirmed the diagnosis of CRPC. However, since the only indication for abiraterone and enzalutamide during the study period was mCRPC we argue that men who filled prescriptions for these drugs had reached the mCRPC state.

In absence of ECOG score, we used CCI to assess general health. CCI has previously been demonstrated to predict overall survival in PCa men quite well in NPCR [38]. A main limitation of our study is also the poor capture of chemotherapy in The In-Patient Registry [39]; only 12% of the men were recorded to have received chemotherapy. In contrast, in a previous report with data from pharmacies on in-patient treatment with chemotherapy between 2008 and 2010 21% of men who died for PCa had received chemotherapy before date of death, and we assume that a substantially higher proportion would have received chemotherapy in this more recent calendar period [40]. Finally, a limitation is the lack of information on the reason for drug stop.

**Strengths and limitations**

The main strength of this study is the virtually complete capture of all men in a country on abiraterone or enzalutamide in 2015–2019. In addition, we had access to data that allowed us to assess time on treatment according to different time intervals, i.e. time without drug supply between fillings. However, this study is not devoid of limitations. We did not have data on PSA levels that confirmed the diagnosis of CRPC. However, since the only indication for abiraterone and enzalutamide during the study period was mCRPC we argue that men who filled prescriptions for these drugs had reached the mCRPC state.

In absence of ECOG score, we used CCI to assess general health. CCI has previously been demonstrated to predict overall survival in PCa men quite well in NPCR [38]. A main limitation of our study is also the poor capture of chemotherapy in The In-Patient Registry [39]; only 12% of the men were recorded to have received chemotherapy. In contrast, in a previous report with data from pharmacies on in-patient treatment with chemotherapy between 2008 and 2010 21% of men who died for PCa had received chemotherapy before date of death, and we assume that a substantially higher proportion would have received chemotherapy in this more recent calendar period [40]. Finally, a limitation is the lack of information on the reason for drug stop.

**Time on treatment in previous published studies**

Time on treatment in our study was considerably shorter than those in RCTs, which was around 14 months for abiraterone and 17 months for enzalutamide in chemo-naïve men and...
around 8 months post-docetaxel for both the drugs [1–4]. Of note, men in our study were considerably older at ART start and had more comorbidities than men in these RCTs. Our findings are in line with a majority of previous registry studies, where time on treatment ranged from 4 to 9 months for abiraterone and from 3 to 11 months for enzalutamide [9–12,16]. Finally, several single and multi-institutional observational studies have reported time on
treatment for ART with a range from 3 up to more than 20 months, likely due to differences in study design, study population, and definition of drug stop [13–15,17–25].

**Implications of time interval between fillings on time on treatment**

No consensus exists on what time interval between fillings should be used when assessing time on treatment for ART drugs from drug registries. In previous registry studies there has been a large range in the allowed time interval without drug supply from 45 to 90 days [9–12,16]. However, as the time interval between two fillings increases, the risk of immortal time bias increases, whereas a short time interval will underestimate time on treatment [41]. Immortal time bias in pharmaco-epidemiological studies refers to a period when follow-up cannot occur [33]. This is the case for a time interval without drug supply between two consecutive fillings: treatment stop cannot occur, but that time is included in time on treatment. In addition, immortal time bias is introduced because only men surviving long enough could have a drug stop date beyond a long interval in drug supply. We assessed time on treatment by use of three different time intervals between two consecutive fillings. Time on treatment increased almost 50% when this interval was allowed to increase from 14 days to no limit. These results underline the importance of reporting the time interval without drug supply in observational studies. However, there was no information on this time interval in 13/17 observational studies that were reviewed ([S1 Table](#)). We argue for the use of a 30-day limit for the time interval without drug supply for ART drugs as a reasonable compromise to be applied in observational studies based on data in Prescribed Drug Registries.

Univariable and multivariable Cox regression model assessing the risk of drug stop including as covariates age at diagnosis, Charlson comorbidity index, PCa risk category, primary treatment at diagnosis and duration of androgen deprivation therapy.

| Age at diagnosis | Univariable HR (95% CI) | Multivariable HR (95% CI) |
|------------------|-------------------------|---------------------------|
| ≤ 60 years       | 1.00 (ref)              | 1.00 (ref)                |
| 60–75 years      | 1.07 (0.97, 1.17)       | 0.98 (0.89, 1.08)         |
| >75 years        | 1.41 (1.27, 1.56)       | 1.15 (1.03, 1.28)         |

| Charlson comorbidity index | Univariable HR (95% CI) | Multivariable HR (95% CI) |
|----------------------------|-------------------------|---------------------------|
| 0                          | 1.00 (ref)              | 1.00 (ref)                |
| 1–2                        | 1.06 (0.99, 1.13)       | 1.06 (0.98, 1.13)         |
| ≥ 3                        | 1.30 (1.21, 1.39)       | 1.29 (1.20, 1.38)         |

| PCa risk category at diagnosis | Univariable HR (95% CI) | Multivariable HR (95% CI) |
|-------------------------------|-------------------------|---------------------------|
| Low/Intermediate-risk         | 1.02 (0.94, 1.10)       | 0.99 (0.91, 1.07)         |
| High-risk/Locally advanced    | 1.17 (1.08, 1.27)       | 0.95 (0.87, 1.04)         |

| Primary treatment | Univariable HR (95% CI) | Multivariable HR (95% CI) |
|-------------------|-------------------------|---------------------------|
| Curative          | 1.00 (ref)              | 1.00 (ref)                |
| Non-curative      | 1.32 (1.24, 1.41)       | 1.22 (1.13, 1.32)         |

| Duration of androgen deprivation therapy | Univariable HR (95% CI) | Multivariable HR (95% CI) |
|------------------------------------------|-------------------------|---------------------------|
| ≤1 year                                  | 1.00 (ref)              | 1.00 (ref)                |
| 1–5 years                                | 0.69 (0.62, 0.77)       | 0.71 (0.63, 0.79)         |
| >5 years                                 | 0.55 (0.49, 0.61)       | 0.58 (0.52, 0.66)         |

Univariable and multivariable Cox regression model assessing the risk of drug stop including as covariates age at diagnosis, Charlson comorbidity index, PCa risk category, primary treatment at diagnosis and duration of androgen deprivation therapy.

* PCa risk category definitions: Low-risk: T1-2, Gleason score 2–6 and PSA <10 ng/ml; Intermediate-risk: T1-2, Gleason score 7 and/or PSA 10 to <20 ng/ml; High-risk: T3 and/or Gleason score 8–10 and/or PSA 20 to <50 ng/ml; Locally advanced:T4 and/or N1 and/or PSA 50 to <100 ng/ml in the absence of distant metastases (M0 or Mx); Metastatic: M1 and/or PSA ≥100 ng/ml.

* Primary treatment was defined as: curative: Radical prostatectomy or prostate radiotherapy; non-curative: Active surveillance, watchful waiting or primary androgen deprivation therapy.

* Duration of androgen deprivation therapy was defined as the time from the date of initiation of GnRH agonist/antagonist, bicalutamide or orchiectomy whichever came first, to the start date of ART.

HR: Hazard ratio; CI: Confidence interval; PCa: Prostate cancer.

https://doi.org/10.1371/journal.pone.0244462.t002
Median and mean time on treatment and adherence

Mean time on treatment was longer than median time on treatment for both abiraterone and enzalutamide, which shows that some men use ART drugs for an extended time, e.g. 10% of men had a time on treatment longer than 23 months for abiraterone and 30 months for enzalutamide. Mean time on treatment is a reliable measure of the average amount of drug used, since it accounts for men with very long or short time on treatment better than median treatment duration [35–37].

In line with previous reports, adherence to the treatment with abiraterone and enzalutamide was above 90% for both the drugs [42–44], likely due to that there is a low risk of short term serious adverse events for men on ART drugs [45].

Predictors of drug stop

In line with previous findings, time on treatment was shorter in old men, in men who had received primary non-curative treatment, in men with a short time on ADT before start of ART, and in men with high comorbidity [46].

Conclusion

In this register-based study of all Swedish men with mCRPC in 2015–2019, time on treatment was 5 months for abiraterone and 8 months for enzalutamide. The concern that men with mCRPC continue to use ART drugs for too long in clinical practice was not substantiated in our study. Adherence to treatment was high. Men with aggressive prostate cancer had shorter time on treatment.

Supporting information

S1 Fig. Flow diagram with patient selection for abiraterone and enzalutamide groups.
(DOCX)

S2 Fig. Adherence to abiraterone and enzalutamide by use of Kaplan-Meier and Weibull curve according to 30-day time interval.
(DOCX)

S3 Fig. Time on treatment with abiraterone and enzalutamide in men with or without prior chemotherapy.
(DOCX)

S1 Table. Studies reporting time on treatment with abiraterone acetate and enzalutamide.
(DOCX)

S1 File. Literature search.
(DOCX)

Acknowledgments

This project was made possible by the continuous work of the National Prostate Cancer Register of Sweden (NPCR) steering group: Pär Stattin (chair), Ingela Franck Lissbrant (deputy chair), Johan Styrke, Camilla Thellenberg Karlsson, Lennart Åström, Hampus Nugin, Stefan Carlsson, Marie Hjälm-Eriksson, David Robinson, Mats Andén, Ola Bratt, Magnus Törnbloom, Johan Stranne, Jonas Hugosson, Maria Nyberg, Olof Akre, Per Fransson, Eva Johansson, Gert Malmberg, Hans Joelsson, Fredrik Sandin, and Karin Hellström.
Region Uppsala has, on behalf of NPCR, made agreements on subscriptions for quarterly reports from Patient-overview Prostate Cancer with Astellas, Sanofi, Janssen, and Bayer, as well as research projects with Astellas, Bayer, and Janssen.

Author Contributions

Conceptualization: Giuseppe Fallara, Hans Garmo, Pär Stattin.

Data curation: Giuseppe Fallara, Hans Garmo.

Formal analysis: Giuseppe Fallara.

Methodology: Giuseppe Fallara, Hans Garmo, Pär Stattin.

Supervision: Hans Garmo, Pär Stattin.

Writing – original draft: Giuseppe Fallara.

Writing – review & editing: Giuseppe Fallara, Ingela Franck Lissbrant, Johan Styrke, Francesco Montorsi, Hans Garmo, Pär Stattin.

References

1. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13: 983–992. https://doi.org/10.1016/S1470-2045(12)70379-0 PMID: 22995653

2. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16: 152–160. https://doi.org/10.1016/S1470-2045(14)71205-7 PMID: 25601341

3. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Non-metastatic, Castration-Resistant Prostate Cancer. New Eng J Med. 2018; 378: 2465–2474. https://doi.org/10.1056/NEJMoa1800536 PMID: 29949494

4. Beer TM, Armstrong AJ, Rathkopf DE, Loriai Y, Sternberg CN, Higano CS, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New Engl J Medicine. 2014; 371: 424–433. https://doi.org/10.1056/nejmoa1405095 PMID: 2481730

5. Cabot RC, Harris NL, Rosenberg ES, Shepard J-AO, Cort AM, Ebeling SH, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New Engl J Med. 2012; 367: 1187–1197. https://doi.org/10.1056/NEJMoa1207506 PMID: 22894553

6. Castration-Resistant Prostate Cancer (2018). 19 May 2020 [cited 19 May 2020]. Available: https://www.auanet.org/guidelines/prostate-cancer-castration-resistant-guideline. Accessed October 1st 2020.

7. National care program for prostate cancer. 4 May 2020. Available: https://kunskapsbanken.cancercentrum.se/diagnoser/prostatacancer/vardprogram. Accessed October 1st 2020.

8. Mottet N, Comford P, Bergh RCN van den, Briers E, Santis MD, Fanti S, et al. EAU—EANM—ESTRO—ESUR—SIIOG Guidelines on Prostate Cancer 2020. EAU—EANM—ESTRO—ESUR—SIIOG Guidelines on Prostate Cancer. Arnhem, The Netherlands; Available: https://uroweb.org/guideline/prostate-cancer/#1.

9. Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsbeger C, Murray N, et al. Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. Eur Urol. 2015; 67: 441–447. https://doi.org/10.1016/j.eururo.2014.01.030 PMID: 24508071

10. Flaig TW, Poturi RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med-us. 2015; 5: 182–191. https://doi.org/10.1002/cam4.576 PMID: 26710718

11. George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovský J, et al. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clin Genitourin Canc. 2020. https://doi.org/10.1016/j.clgc.2019.12.019 PMID: 32057714
12. Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA. Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. J Manag Care Spec Ph. 2017; 23: 225–235. https://doi.org/10.18553/jmcp.2016.16233 PMID: 28125362

13. Svensson J, Andersson E, Persson U, Edeking T, Omanor A, Ahlgren G. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden. Scand J Urol. 2016; 50: 286–291. https://doi.org/10.3109/21681805.2016.1172254 PMID: 27109827

14. Verzoni E, Giorgi UD, Derosa L, Caffo O, Boccardo F, Facchini G, et al. Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget. 2016; 7: 40085–40094. https://doi.org/10.18632/oncotarget.9485 PMID: 27223078

15. Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, et al. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017; 77: 1303–1311. https://doi.org/10.1002/pros.23390 PMID: 28762529

16. Schultz N, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, et al. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis. Adv Ther. 2018; 36: 1859–1865. https://doi.org/10.1007/s12325-018-0774-1 PMID: 30191463

17. Boegemann M, Khakzar S, Bera G, Birite A, Dopchie C, Dourthe L-M, et al. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. Bmc Cancer. 2019; 19: 60. https://doi.org/10.1186/s12885-019-5280-6 PMID: 30642291

18. Leibowitz-Amit R, Seah J-A, Atenafu EG, Templeton AJ, Vera-Badillo FE, Alimohamed N, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer: an international, real-world, retrospective study of patients with the germline homozygous HSD3B1 c.1245C genotype. Ann Oncol Official J European Soc Medical Oncol. 2019; 30: 1662-1672. https://doi.org/10.1016/j.annonc.2019.09.028 PMID: 31558383

19. Ramalingam S, Humenuik MS, Hu R, Rasmussen J, Wu Y, et al. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer. Urologic Oncol Seminars Orig Investigations. 2017; 35: 418–424. https://doi.org/10.1016/j.urol incid.2017.02.008 PMID: 28395931

20. Salem S, Komisarenko M, Timilshina N, Martin L, Grewal R, Alibhai S, et al. Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer. Clin Oncol. 2017; 29: 601–608. https://doi.org/10.1016/j.clon.2017.03.010 PMID: 28395931

21. Biró K, Buda B, Szönyi M, Kúranyak Z, Gyergyay F, Nagyiványi K, et al. Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients. Urologic Oncol Seminars Orig Investigations. 2018; 36: 81.e1-81.e7. https://doi.org/10.1016/j.urolinc.2017.10.015 PMID: 29153623

22. Beardo P, Osman I, José BS, Llarena R, Congrado B, Campa J, et al. Safety and outcomes of new generation hormone-therapy in elderly chemotherapy-naive metastatic castration-resistant prostate cancer patients in the real world. Arch Gerontol Geriat. 2019; 82: 179–185. https://doi.org/10.1016/j.archger.2019.02.008 PMID: 30818172

23. Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moire L, Gravis G, et al. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. Bmc Cancer. 2015; 15: 222. https://doi.org/10.1186/s12885-015-1257-2 PMID: 25884302

24. Alghazali M, Lögren A, Jergensen L, Svensson M, Fagerlund K, Bjartell A. A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Scand J Urol. 2019; 53: 1–7. https://doi.org/10.1080/21681805.2018.1555187 PMID: 30636472

25. Lu C, Terbuch A, Dalling D, Wang H, Chen Y, et al. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germ line homozygous HSD3B1 c.1245C genotype. Ann Oncol Official J European Soc Medical Oncol. 2020; https://doi.org/10.1002/1099-015.2020.00.047 PMID: 32387417

26. Hemelrijk MV, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2012; 42: 956–967. https://doi.org/10.1093/ije/dys068 PMID: 22561842

27. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register—a sample survey for year 1998. Acta Oncol. 2009; 48: 27–33. https://doi.org/10.1080/02841860802247664 PMID: 18767000
28. Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lisbrant IF, Carlsson S, et al. Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden. Frontiers Medicine. 2019; 6: 51. https://doi.org/10.3389/fmed.2019.00051 PMID: 30968024

29. Wettermark B, Hammar N, Michael Fored C, Leimaris A, Olausson PO, Bergman U, et al. The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemi Dr S. 2007; 16: 726–735. https://doi.org/10.1002/pds.1294 PMID: 16897791

30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity. J Chronic Dis. 1987; 40: 373–383. https://doi.org/10.1016/0021-9681(87)90171-8 PMID: 3558716

31. Fall K, Strömberg F, Rosell J, Andrén O, Varenhorst E, Group TS-ERPC. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008; 42: 352–357. https://doi.org/10.1080/00365590802078583 PMID: 18609293

32. Nationellt vårdprogram prostatacancer. In: Nationellt vårdprogram prostatacancer [Internet], 30 May 2020 [cited 30 May 2020]. Available: https://kunskapsbanken.cancercentrum.se/diagnoser/prostatacancer/vardprogram. Accessed October 1st 2020.

33. Suissa S. Immortal Time Bias in Pharmacoepidemiology. Am J Epidemiol. 2008; 167: 492–499. https://doi.org/10.1093/aje/kwm324 PMID: 18056625

34. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidem Dr S. 2006; 15: 565–574. https://doi.org/10.1002/pds.1230 PMID: 16514590

35. Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials. J Clin Oncol Official J Am Soc Clin Oncol. 2016; 34: 1813–9. https://doi.org/10.1200/JCO.2015.64.2488 PMID: 26884584

36. Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, et al. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. Jama Oncol. 2017; 3: 1692. https://doi.org/10.1001/jamaoncol.2017.2797 PMID: 28975283

37. Zhao L, Caggiott B, Tian L, Uno H, Pfeffer MA, Solomon SD, et al. On the restricted mean survival time curve in survival analysis: On the Restricted Mean Survival Time Curve in Survival Analysis. Biometrics. 2015; 72: 215–221. https://doi.org/10.1111/biom.12384 PMID: 26302329

38. Hemelrijck MV, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. Bju Int. 2015; 117: 507–514. https://doi.org/10.1111/bju.13059 PMID: 25604807

39. Lisbrant IF, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018; 52: 143–150. https://doi.org/10.1080/21681805.2018.1426039 PMID: 29385878

40. Lisbrant IF, Garmo H, Widmark A, Stattn P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013; 52: 1593–1601. https://doi.org/10.3109/0284186X.2013.770164 PMID: 23427879

41. Weberpals J, Jansen L, Herk-Sukel MPP van, Kuiper JG, Aarts MJ, Vissers PAJ, et al. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis. Eur J Epidemiol. 2017; 32: 1019–1031. https://doi.org/10.1007/s10654-017-0304-5 PMID: 28864987

42. Behl AS, Ellis LA, Pilon D, Xiao Y, Lefebvre P. Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide. Am Heal Drug Benefits. 2017; 10: 296–303.

43. Al-Ali BM, Kramer G, Madersbacher S, Berger I. Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization. Wien Klin Wochenschr. 2016; 129: 380–384. https://doi.org/10.1007/s00508-016-1967-9 PMID: 27596230

44. Lafeuille M-H, Grittner AM, Lefebvre P, Ellis L, McKenzie RS, Slaton T, et al. Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer. J Manag Care Pharm. 2014; 20: 477–484. https://doi.org/10.18553/jmcp.2014.20.5.477 PMID: 24761819

45. Nunzio CD, Lombardo R, Terna G, Voglino O, Sica A, Baldassari V, et al. Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. Prostate Cancer P D. 2018; 1: 1–8. https://doi.org/10.1038/41391-019-0182-x PMID: 31685981

46. McKay RR, Werner L, Fiorillo M, Nakabayashi M, Kantoff PW, Taplin M-E. Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. Prostate Cancer P D. 2016; 19: 398–405. https://doi.org/10.1038/pcan.2016.31 PMID: 27502737